31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry

Abstract

Neurotrophic Tyrosine Receptor Kinase gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the tropomyosin receptor kinases TRKA, TRKB and TRKC, respectively) are oncogenic drivers. The overall prevalence of NTRK fusion-positive tumors is ∼0.30%, though frequencies vary by tumor type, with >90% reported for rare tumor types such as secretory carcinoma of the breast and salivary glands. In Europe, two TRK inhibitors (entrectinib and larotrectinib) received tumor-agnostic approval. A very good clinical activity and a favorable overall safety profile was shown for both, making this new targeted approach highly relevant for patients with NTRK-fused tumors.